Trusted Resources: Evidence & Education
Scientific literature and patient education texts
The first South American case of pre-implantation genetic diagnosis to select compatible embryo for cord blood transplantation as treatment for sickle cell anemia
source: JBRA Assisted Reproduction
year: 2018
authors: Martinhago CD, Endo KR, Oliveira MA, Dias AM, Pereira GS, Azzolini AM, Estrada PR, Bruzaca CG, Martinhago ACN
summary/abstract:Sickle cell anemia is an inherited systemic hemoglobinopathy that affects hemoglobin production in red blood cells, leading to early morbidity and mortality. It is caused by a homozygous nucleotide substitution (c.20A>T) in the β-globin gene (HBB) that changes a glutamic acid to a valine in the protein.
We present a case report of a fertile couple, both carriers of the sickle cell anemia mutation, with one affected daughter. Six cycles of assisted reproductive techniques were performed, resulting in 53 embryos in cleavage stage. Each embryo was biopsied and analyzed for pre-implantation genetic diagnosis (PGD) by fluorescent polymerase chain reaction, using polymorphic markers of the region of interest followed by capillary electrophoresis in an automated genetic analyzer.
HLA Compatible and normal embryos for the mutation represented 3 (5.66%); while the carriers and compatible 6 (11.32%); therefore, embryos matching those of the affected daughter represented 9 (16.98%). A selected embryo in blastocyst stage was transferred, resulting in a healthy male newborn, who had the umbilical cord blood cells collected and stored.
The affected daughter was immunosuppressed and received transplanted cells from the umbilical cord blood of her brother; the treatment was successful. Embryo selection using PGD technologies represent the most effective treatment plan for parents who want to have a healthy child, and it could cure another child already affected by inherited hemoglobinopathy.
organization: Chromosome Medicina Genômica, South America
DOI: 10.5935/1518-0557.20180017
read more full text
Related Content
-
Family cord blood banking for sickle cell disease: a twenty-year experience in two dedicated public cord blood banksEfforts to implement family cord blood b...
-
Inaugural Event, World Cord Blood Day 2017, Highlights Non-Controversial Source of Stem CellsWorld Cord Blood Day (November 15th) wil...
-
Sickle Cell Disease Association of America, Inc. Awards Community Based Organizations With $2,033,080 for Newborn Sc...The Sickle Cell Disease Association of A...
-
Why do blood types matter? – Natalie S. Hodgehttps://www.youtube.com/watch?v=xfZhb6lm...
-
Testing Gene Editing for Sickle Cell Diseasehttps://www.youtube.com/watch?v=RGetNC2B...
-
23andMe, Morehouse School of Medicine and the Sickle Cell Foundation of Georgia Inc. launches the Sickle Cell Carrie...Atlanta, GA: April 11, 2023 — 23andMe ...
-
MARAC Statement: Health Insurance Coverage for Hematopoietic Stem Cell Transplant for Sickle Cell Disease from HLA-m...Hematopoietic stem cell transplant for s...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.